版本:
中国

BRIEF-BioMarin reviews status of Exon 51 composition of matter

Sept 21 BioMarin Pharmaceutical Inc :

* To seek review of patent trial and appeal board ruling, for composition of matter claims related to exon 51 skipping antisense oligonucleotides

* Biomarin reviews status of exon 51 composition of matter and method of use patent interference cases against Sarepta Therapeutics

* Anticipates final ruling from federal circuit court of appeals on ptab decision related to mou patent in late 2017/early 2018 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐